Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Inclusion Criteria:

• Subjects with a diagnosis of CD20 and CD22-positive, follicular lymphoma, who havereceived 1 or 2 prior regimens, at least 1 of which should have containedadministration of rituximab (either as a single agent or in combination).

• Age 18 years or older.

• ECOG performance status <= 2.

• ANC >= 1.5 x 10^9/L (1500/mL) and platelets >= 75 x 10^9/L (75,000/mL), serumcreatinine <= 1.5 x ULN and urine protein to creatinine ratio of <= 0.5, totalbilirubin <= 1.5 x ULN, AST and ALT <= 2.5 x ULN.

• At least 1 measurable disease lesion that is >= 1.5 cm x 1.5 cm by CT or MRI, in anarea of no prior radiation therapy, or documented progression in an area that waspreviously irradiated.

Exclusion Criteria:

• Subjects with clinical evidence of transformation to a more aggressive subtype oflymphoma or grade 3b follicular lymphoma.

• Subjects whose disease is rituximab refractory, meaning that they did not have a CR orPR, or that they experienced disease progression within 6 months from the initiationof the rituximab or rituximab containing treatment regimen administered immediatelypreceding study enrollment.